Aquestive Therapeutics (NASDAQ:AQST) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Aquestive Therapeutics (NASDAQ:AQST) from a sell rating to a hold rating in a research report report published on Saturday,Wall Street Zen reports.

Other analysts also recently issued reports about the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $11.00 target price on shares of Aquestive Therapeutics in a research report on Thursday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aquestive Therapeutics in a report on Friday, July 17th. Finally, HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Aquestive Therapeutics in a research note on Monday, August 24th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $9.17.

Aquestive Therapeutics Stock Up 2.1%

AQST stock opened at $4.88 on Friday. The stock has a market capitalization of $612.49 million, a price-to-earnings ratio of -7.51 and a beta of 1.48. Aquestive Therapeutics has a 52-week low of $2.93 and a 52-week high of $7.55. The stock’s fifty day simple moving average is $4.40 and its 200-day simple moving average is $4.26.

Aquestive Therapeutics (NASDAQ:AQST) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.08). The business had revenue of $13.82 million during the quarter, compared to analysts’ expectations of $11.42 million. As a group, analysts anticipate that Aquestive Therapeutics will post -0.5 earnings per share for the current fiscal year.

Insider Transactions at Aquestive Therapeutics

In related news, Director Julie Krop sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $5.02, for a total transaction of $125,500.00. Following the transaction, the director directly owned 25,000 shares of the company’s stock, valued at approximately $125,500. The trade was a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Sherry Korczynski sold 8,750 shares of the company’s stock in a transaction that occurred on Wednesday, September 9th. The stock was sold at an average price of $5.22, for a total value of $45,675.00. Following the completion of the transaction, the insider owned 235,689 shares of the company’s stock, valued at approximately $1,230,296.58. This represents a 3.58% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.81% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Aquestive Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Elevation Point Wealth Partners LLC purchased a new stake in shares of Aquestive Therapeutics during the first quarter worth about $42,000. ADAR1 Capital Management LLC grew its stake in Aquestive Therapeutics by 103.9% during the 1st quarter. ADAR1 Capital Management LLC now owns 10,000 shares of the company’s stock valued at $42,000 after purchasing an additional 264,000 shares in the last quarter. Wealthfront Advisers LLC acquired a new stake in Aquestive Therapeutics during the 2nd quarter valued at approximately $44,000. Legal & General Group Plc acquired a new stake in Aquestive Therapeutics during the 2nd quarter valued at approximately $44,000. Finally, Keating Financial Advisory Services Inc. purchased a new stake in Aquestive Therapeutics during the 2nd quarter worth approximately $52,000. Institutional investors and hedge funds own 32.45% of the company’s stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines delivered through its PharmFilm technology. The company’s dissolvable oral-film platform is designed to provide alternatives to conventional tablets, capsules and injectable therapies, with potential benefits for patients who have difficulty swallowing or require rapid, convenient administration.

Aquestive’s commercial products include Exservan, an oral film formulation of riluzole for people with amyotrophic lateral sclerosis; Libervant, a buccal film formulation of diazepam for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity; and Sympazan, an oral film formulation of clonazepam for the treatment of seizures associated with Lennox-Gastaut syndrome.